Tamoxifen

Overview

Tamoxifen is a SERM — it blocks estrogen in some tissues (like breast) while acting differently elsewhere. In the enhancement context it is used to manage gynecomastia and as a central component of post-cycle therapy (PCT).

It is also one of the oldest and best-documented drugs in this entire field, which is worth stating plainly: very little else discussed on this site has decades of clinical data behind it.

Mechanism of Action

At the breast, tamoxifen blocks the estrogen receptor, which is why it helps with gyno. In the hypothalamus and pituitary it blocks estrogen's negative feedback, so LH and FSH output rises and the testes are stimulated to resume testosterone production — the basis of its PCT role.

Two consequences of this are easy to miss:

It does not lower estradiol. An aromatase inhibitor reduces how much estradiol exists. Tamoxifen leaves the level alone — often raising it — and blocks the receptor only where it matters. If the problem is a genuinely high estradiol reading, tamoxifen is not the tool that changes the number.

It is a prodrug. Tamoxifen itself is only weakly active. The liver enzyme CYP2D6 converts it into endoxifen, which does most of the work. That detail becomes important below.

Typical Context

Two main uses: managing early gyno symptoms, and PCT after a cycle to speed the recovery of the natural hormone axis.

For PCT, the timing follows the ester, not the calendar. Starting while the compound is still circulating means suppressing an axis that is suppressed anyway — those weeks are simply lost. As a rough orientation: a few days after the last propionate injection, roughly two weeks after enanthate or cypionate, and considerably longer after undecanoate.

The CYP2D6 problem

This is the most useful thing on this page, and it is rarely mentioned.

Because tamoxifen has to be converted by CYP2D6 to work, anything that blocks that enzyme blunts the drug. The strongest inhibitors are common antidepressants — paroxetine, fluoxetine and bupropion in particular. Taken alongside, they can reduce active endoxifen substantially.

The practical consequence: someone on an SSRI runs a full PCT, feels nothing, concludes the tamoxifen was counterfeit, and buys from a different source. The tamoxifen may have been fine.

Sertraline, escitalopram and venlafaxine interfere far less. Raloxifene is not a prodrug and does not depend on this pathway at all, which is one reason to prefer it in this situation. If you take any prescribed medication, this belongs in a conversation with the doctor who prescribed it rather than being solved by guesswork.

Tamoxifen or raloxifene for gynecomastia

Both block the estrogen receptor at breast tissue. The practical difference is which stage of tissue they still reach.

Tamoxifen is the better-documented option for early, tender, recent-onset symptoms. For gyno that is already established — a firm lump behind the nipple, present for months — raloxifene has the stronger reputation, and neither reliably reverses tissue that has turned fibrotic.

The uncomfortable part is that timing matters more than the choice between them. Acting in the first weeks of symptoms gives a real chance. Acting after a year usually leaves surgery as the only route.

Not alongside an aromatase inhibitor

Running tamoxifen and an aromatase inhibitor together is common and mostly counterproductive. The two interact pharmacologically, and the combination has been studied clinically — it performed worse than the aromatase inhibitor alone.

They also address different problems. If estradiol is genuinely too high, lower it, or lower the dose driving it. If the problem is receptor-level breast symptoms, block the receptor. Doing both at once usually reflects uncertainty about which problem is actually present — and that uncertainty is what a sensitive estradiol test resolves.

Side Effects & Risks

• Mood changes and reduced libido during use
• Raised risk of venous thromboembolism — clots in the deep veins or lungs
• Rarely, visual disturbances; with prolonged high-dose use, retinal changes
• Lowers IGF-1 by roughly a fifth, which works against the goal of holding onto muscle during recovery

The clotting risk deserves attention here for a reason it does not usually get. Androgens raise hematocrit, and thicker blood is itself a clotting risk factor. Tamoxifen adds a second, independent one. Someone finishing a cycle with hematocrit at the top of the range and starting tamoxifen has stacked two risks that are individually modest and together are not. That is an argument for knowing your hematocrit before PCT — not for avoiding tamoxifen.

Blood Work & Monitoring

• LH, FSH, total testosterone — to judge recovery during and after PCT
• Estradiol (sensitive assay) — for context alongside the above
• Hematocrit — before starting, for the reason described above
• Liver panel during longer use

One note on reading PCT bloodwork: LH rising is the first sign the axis is responding, and it moves before testosterone does. Testing testosterone alone two weeks in and seeing a low number tells you almost nothing.

Harm-Reduction Notes

• Have the PCT plan and the medication ready before starting a cycle, not after
• Base PCT timing on when the compounds clear, not on a fixed number of weeks
• Check what else you take for CYP2D6 inhibition before concluding the drug does not work
• Know your hematocrit before adding a second clotting risk factor
• Gyno that is lumpy and established may not resolve with a SERM alone — seek medical advice early rather than experimenting for months